Novartis' Exelon recommended for approval by FDA advisory committee

By Elaine Rigoli

Tampa, Fla., May 17 - Novartis announced that Exelon (rivastigmine tartrate) received a favorable opinion from the Peripheral and Central Nervous System Drugs Advisory Committee of the Food and Drug Administration for the treatment of mild to moderate dementia associated with Parkinson's disease.

If approved, Exelon would be the first and only medication available for the treatment of dementia associated with Parkinson's disease, according to a news release.

Exelon is currently approved for the treatment of mild to moderate Alzheimer's disease.

About 40% of patients with Parkinson's disease are estimated to also develop dementia, which can have a devastating effect on patients and their families, the release said.

Basel, Switzerland-based Novartis develops prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, gastrointestinal and respiratory areas.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.